Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma

NCT07152678 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Nivolumab (240 mg)
RADIATION: Brachytherapy

Sponsor

National Taiwan University Hospital